ClinicalTrials.gg
CompletedNCT02029716Updated May 28, 2025

RTA 408 Lotion in Healthy Volunteers

A Phase 1 interventional study of RTA 408 Lotion 0.5%, 1%, 3% and Lotion vehicle/placebo in Healthy, sponsored by Biogen. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-28.

Sponsored by Biogen · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
109
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,173 studies in Inflammation with a site in United States — 161 open to participants now, 214 under way, 6 of them phase 3. Inflammation · United States.

Enrollment
197th of 956
109 · median 45
Started
2013
with 48 others
Phase 1
114 of 1,173
19 open now
Registered
487th of 1,173
by date

Among the 1,173 studies in Inflammation with a site in United States, this one is the 197th largest by enrollment of the 956 interventional ones that give a count, is one of 49 that started in 2013, is one of 114 in phase 1, and was the 487th registered.

Inflammation

3,541 studies on the registry are indexed under Inflammation; 646 are open to participants now.

Browse Inflammation studies →

Open to participants now

161 of the 1,173 studies in Inflammation with a site in United States are open now. Recruiting first, the newest first:

156 more — sign in →

All 161 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 461 Inflammation studies recruiting now, 174 (38%) set no upper age limit and 206 (45%) stop at 75 or younger; 56 take children under 18; 165 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,173 studies in Inflammation with a site in United States, or all of them as a file.
02

Study summary

This study is a first-in-human study of a topical dermal lotion formulation of RTA 408, a novel small molecule which suppresses oxidative stress and inflammation. In this study, the safety, local pharmacodynamics (PD), and systemic pharmacokinetics (PK) of RTA 408 will be evaluated following topical application of RTA 408 Lotion to healthy volunteers. This study will be conducted in three parts. In Part A of the study, healthy volunteers will have RTA 408 Lotion Vehicle and RTA 408 Lotion (0.5%, 1%, and 3%) applied to a small skin surface area (four individual 4-cm2 sites; 16 cm2 total area) twice daily for 14 days to assess the local skin tolerability, local PD, and systemic PK of these treatments. Part B will be conducted after completion of Part A and will assess the safety, tolerability, local PD, and systemic PK of RTA 408 Lotion applied topically twice daily for 14 days to a larger skin surface area (\~100 cm2). Part C will be conducted after completion of Part B and will assess the safety, tolerability, local PD, and systemic PK of RTA 408 Lotion applied topically twice daily for 28 days to a larger skin surface area (\~500 cm2). The maximum tolerated drug concentration in Part A will be used in Part B and Part C.

Approximately 32 healthy adult volunteers will be enrolled in this study with 12 volunteers in Part A and 10 volunteers each, in Parts B and C.

03

Conditions studied

  • Healthy

Browse trials for

Keywords

  • RTA 408
  • RTA 408 Lotion
  • Oxidative stress
  • Inflammation
  • Volunteers
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects must voluntarily give written and agree to comply with visit schedule including willingness to remain at the study site;
  2. Subjects must be adults (male or female), ages 18 to 65, inclusive;
  3. Subjects must have healthy skin on which reddening can easily be recognized (Fitzpatrick type I-IV skin);
  4. The planned application site must have unbroken skin (ie, free from cuts, scratches, and abrasions), and be free of excessive hair, tattoos, or other abnormality that, in the Investigator's judgement, would interfere with the conduct of the study;
  5. Subjects must have a (BMI) of ≥18 kg/m2 and ≤32 kg/m2;
  6. Women must be of non- and may not be pregnant, lactating, or breast-feeding.
  7. Male subjects must agree that they and any female partners will use 2 acceptable forms of , 1 of which must be a condom, until 3 months after the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  1. Persons with Fitzpatrick skin types V or VI;
  2. Presence of active inflammatory dermatoses (eg, atopic dermatitis, psoriasis), bacterial, viral, or fungal skin infections;
  3. History of drug allergies including allergies to any of the components of the product and/or clinically significant food allergies as determined by the Investigator;
  4. Use of any alcohol or methylxanthine-containing beverages or food (eg, coffee, tea, cola, chocolate, and "power drinks") from 72 hours prior to the first dose of study drug until after the last protocol specified blood sample;
  5. Use of any tobacco products, nicotine-containing products, or pharmacologic smoking cessation therapy during the 3 months immediately prior to the first dose of study drug, and/or not willing or able to refrain from use of any of these products for the duration of the study until after the last protocol specified blood sample;
  6. History of alcohol abuse within 2 years of the Screening Visit, in the judgment of the Investigator, or average weekly alcohol consumption of >14 alcoholic drinks. One drink is defined as 1 glass of beer (approximately 10 oz to 12 oz) or 1 can (12 oz) of beer, 1 glass of wine (approximately 4 oz to 5 oz), or 1 glass of distilled spirits (hard liquor) containing 1 oz of the liquor (1 oz of liquid is approximately 30 mL);
  7. Positive breath test for alcohol at the Screening Visit or at Day -1;
  8. History of drug abuse within 2 years of the Screening Visit, in the judgment of the Investigator;
  9. Positive urine test for cotinine or drugs of abuse (ie, opiates, methadone, cocaine, amphetamines, cannabinoids, barbiturates, benzodiazepines) at the Screening Visit or at Day -1;
  10. Not willing to abstain from strenuous exercise (eg, heavy lifting, weight training, calisthenics, aerobics) for at least 48 hours prior to admission to the investigational site until after the last protocol specified blood sample;
  11. Use of substances known to be strong inhibitors or inducers of Cytochrome P450 (CYP450) enzymes (eg, ritonavir, ketoconazole, nefazodone, grapefruit juice) within 14 days prior to the first dose of study drug through the last study visit. Chronic exposure to enzyme inducers such as paint solvents or pesticides or other investigational drug use within 30 days prior to study drug administration;
  12. Use of prescription drugs, dietary supplements, or herbal remedies (including products applied topically) within 14 days or 5 half-lives (whichever is longer) prior to the first dose of study drug; use of non-prescription drugs or vitamins (including products applied topically) within 7 days prior to the first dose of study drug; or unwillingness to refrain from taking any such medication until after the last protocol specified blood sample;
  13. Donation of whole blood >450 mL or blood products within 56 days prior to admission to the investigational site;
  14. Use of any investigational drug within 30 days or 5 half-lives of the previous investigational drug prior to the first dose of study drug in this study, whichever is longer;
  15. Positive screen for (HIV), , and/or at the Screening Visit;
  16. Acute illness accompanied by temperature ≥101○F within 5 days prior to study drug administration;
  17. Presence or history of cancer within 5 years prior to the Screening Visit (other than basal cell skin cancer in a location other than the back and without active lesions and adequately treated carcinoma in situ of cervix);
  18. Presence or history of any significant cardiovascular, gastrointestinal, hepatic, renal, pulmonary, hematologic, endocrine, immunologic, dermatologic, neurologic disease
  19. Presence of any other condition (including surgery) known to interfere with the absorption, distribution, metabolism, or excretion of medicines. History of appendectomy and cholecystectomy is permitted;
  20. Any abnormal clinical laboratory value or abnormal (ECG) finding at the Screening Visit or at Day -1 that is considered clinically significant by the Investigator;
  21. (INR) >1.5 at the Screening Visit;
  22. Men whose female partner is pregnant or lactating, or who plans to become pregnant during the study or within 3 months after the end of the study;
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
109 participants (actual)

Study arms

  • Placebo comparator
    Part A

    RTA 408 lotion 0.5%, 1%, and 3% and lotion vehicle applied to skin twice daily for 14 days

    Drug: RTA 408 Lotion 0.5%, 1%, 3% · Drug: Lotion vehicle/placebo

  • Experimental
    Part B

    Up to 3% RTA 408 lotion applied to skin twice daily for 14 days (% concentration to be determined, based on results from Part A, \~100 cm2 surface area)

    Drug: RTA 408 Lotion 0.5%, 1%, 3%

  • Experimental
    Part C

    3% RTA 408 lotion applied to skin twice daily for 28 days (\~500 cm2 surface area)

    Drug: RTA 408 Lotion 0.5%, 1%, 3%

Interventions

06

What researchers measure

Primary outcomes

  1. Skin changes or redness following topical application of RTA 408 lotion or lotion vehicle

    Time frame: 14 days

07

Study locations

1 site
  • Medpace Clinical Pharmacology Unit
    Cincinnati, Ohio 45212, United States
08

References and documents

Publications

  • Reisman SA, Goldsberry AR, Lee CY, O'Grady ML, Proksch JW, Ward KW, Meyer CJ. Topical application of RTA 408 lotion activates Nrf2 in human skin and is well-tolerated by healthy human volunteers. BMC Dermatol. 2015 Jul 14;15:10. doi: 10.1186/s12895-015-0029-7. PubMed 26170027 ↗

Individual participant data

Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2013 to primary completion in Apr 2014, 3 months.

Of 82 phase 1 interventional studies under Inflammation, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 51. This study's 3 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 30, 2013
First posted
Jan 8, 2014
StartActual
Dec 31, 2013
Primary completionActual
Apr 1, 2014
CompletionActual
Apr 1, 2014
Last update
May 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02029716
Lead sponsor
Biogen
Collaborators
AbbVie
Responsible party
Sponsor
First posted
Jan 8, 2014
Start date
Dec 31, 2013
Primary completion
Apr 1, 2014
Completion
Apr 1, 2014
Last update
May 28, 2025

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Omaveloxolone

Start the discussion